Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V.

Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22.

PMID:
30467838
2.

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

Lim SH, Linton KM, Collins GP, Dhondt J, Caddy J, Rossiter L, Vadher K, Fines K, Rogers LE, Fernando D, Stanton L, Davies AJ, Johnson PWM, Griffiths G.

Trials. 2018 Nov 9;19(1):619. doi: 10.1186/s13063-018-2996-6.

3.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
30380386
4.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

PMID:
30332497
5.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

6.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
7.

Seronegative antibody-mediated neurology after immune checkpoint inhibitors.

Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W, Collins GP, Cossins J, Beeson D, Steven N, Maddison P, Rinaldi S, Jacob S, Irani SR.

Ann Clin Transl Neurol. 2018 Mar 25;5(5):640-645. doi: 10.1002/acn3.547. eCollection 2018 May.

8.

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D.

Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

9.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.

10.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

PMID:
29394125
11.

Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.

Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F.

Leuk Lymphoma. 2018 Sep;59(9):2113-2120. doi: 10.1080/10428194.2017.1421762. Epub 2018 Jan 16.

PMID:
29334819
12.

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.

Ait-Tahar K, Anderson AP, Barnardo M, Collins GP, Hatton CSR, Banham AH, Pulford K.

Adv Hematol. 2017;2017:6527306. doi: 10.1155/2017/6527306. Epub 2017 Oct 24.

13.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.

Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP.

Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Erratum in: Br J Haematol. 2018 Jan;180(2):309.

PMID:
28857136
14.

Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.

Hildyard C, Shiekh S, Browning J, Collins GP.

Clin Med Insights Blood Disord. 2017 Apr 24;10:1179545X17705863. doi: 10.1177/1179545X17705863. eCollection 2017.

15.

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.

PMID:
28342183
16.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R.

Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.

17.

Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment.

Aznar MC, Darby S, Collins GP, Cutter D.

Lancet Oncol. 2016 Sep;17(9):1189-90. doi: 10.1016/S1470-2045(16)30283-2. Epub 2016 Jul 25. No abstract available.

PMID:
27470082
18.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
19.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.

Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS.

Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9.

PMID:
26956150
20.

Acute EBV masquerading as peripheral T-cell lymphoma.

Zhang XY, Collins GP, Soilleux E, Eyre TA.

BMJ Case Rep. 2016 Feb 2;2016. pii: bcr2015213573. doi: 10.1136/bcr-2015-213573.

21.

Science and Culture: Kirigami and technology cut a fine figure, together.

Collins GP.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):240-1. doi: 10.1073/pnas.1523311113. No abstract available.

22.

Focal segmental glomerulosclerosis in a patient with mantle cell lymphoma.

Hindocha S, Gopaluni S, Collins GP, Shenbagaraman P.

BMJ Case Rep. 2015 Sep 9;2015. pii: bcr2015211765. doi: 10.1136/bcr-2015-211765.

23.

Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.

Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS.

Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29. No abstract available.

PMID:
26223361
24.

Immune checkpoint inhibition in lymphoid disease.

Eyre TA, Collins GP.

Br J Haematol. 2015 Aug;170(3):291-304. doi: 10.1111/bjh.13397. Epub 2015 Mar 30. Review.

PMID:
25824455
25.

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.

Collins GP, Eyre TA, Linton KM, Radford J, Vallance GD, Soilleux E, Hatton C.

Br J Haematol. 2015 Sep;170(6):886-90. doi: 10.1111/bjh.13333. Epub 2015 Feb 26. No abstract available.

PMID:
25721307
26.

Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.

Eyre TA, Gatter K, Collins GP, Hall GW, Watson C, Hatton CS.

Am J Hematol. 2015 Jun;90(6):E103-10. doi: 10.1002/ajh.23989. Epub 2015 May 4.

27.

Management and controversies of classical Hodgkin lymphoma in pregnancy.

Eyre TA, Lau IJ, Mackillop L, Collins GP.

Br J Haematol. 2015 Jun;169(5):613-30. doi: 10.1111/bjh.13327. Epub 2015 Feb 13. Review.

PMID:
25684034
28.

A rare but potentially fatal cause of diarrhoea and weight loss: enteropathy-associated T-cell lymphoma.

Wali GN, Tyrrell HE, Collins GP, Eagleton HJ.

BMJ Case Rep. 2015 Jan 7;2015. pii: bcr2014204125. doi: 10.1136/bcr-2014-204125.

29.

Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.

Dhalla F, Murray S, Sadler R, Chaigne-Delalande B, Sadaoka T, Soilleux E, Uzel G, Miller J, Collins GP, Hatton CS, Bhole M, Ferry B, Chapel HM, Cohen JI, Patel SY.

J Clin Immunol. 2015 Feb;35(2):112-8. doi: 10.1007/s10875-014-0116-2. Epub 2014 Dec 13. Review.

30.

Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).

Sims MC, Newell K, Eyre TA, Hatton C, Collins GP.

Br J Haematol. 2015 May;169(3):452-5. doi: 10.1111/bjh.13226. Epub 2014 Nov 16. No abstract available.

PMID:
25399667
31.

A 72-year-old woman with a persistent cough and abnormal chest X-ray.

Corcoran JP, Moore AJ, Ho LP, Davies SJ, Collins GP.

Br J Hosp Med (Lond). 2014 Nov;75(11):652-3. doi: 10.12968/hmed.2014.75.11.652. No abstract available.

PMID:
25383438
32.

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.

Eyre TA, Collins GP, Goldstone AH, Cwynarski K.

Br J Haematol. 2014 Aug;166(3):336-51. doi: 10.1111/bjh.12945. Epub 2014 May 19. Review.

PMID:
24842496
33.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.

Eyre TA, Khan D, Hall GW, Collins GP.

Eur J Haematol. 2014 Dec;93(6):455-68. doi: 10.1111/ejh.12360. Epub 2014 May 21. Review.

PMID:
24766435
34.

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.

Rule S, Collins GP, Samanta K.

J Med Econ. 2014 Jul;17(7):459-68. doi: 10.3111/13696998.2014.914033. Epub 2014 May 7.

PMID:
24720836
35.

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Eyre TA, Gooding S, Patel I, Moore N, Hatton C, Collins GP.

Int J Hematol. 2014 Jun;99(6):798-800. doi: 10.1007/s12185-014-1555-5. Epub 2014 Mar 2.

PMID:
24584910
36.

T-cell/histiocyte-rich large B-cell lymphoma--transformation of nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow.

Eyre TA, King AJ, Hatton C, Collins GP.

Eur J Haematol. 2014 Jun;92(6):550-1. doi: 10.1111/ejh.12278. Epub 2014 Feb 21. No abstract available.

PMID:
24483596
37.

Classical Hodgkin's lymphoma: past, present and future perspectives.

Eyre TA, King AJ, Collins GP.

Br J Hosp Med (Lond). 2013 Nov;74(11):612-8. Review. No abstract available.

PMID:
24220522
38.

Current treatment and future prospects for peripheral T-cell lymphoma.

Eyre TA, Collins GP.

Drugs Today (Barc). 2013 Oct;49(10):631-46. doi: 10.1358/dot.2013.49.10.2025391. Review.

PMID:
24191256
39.

Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.

Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R.

Transfusion. 2014 May;54(5):1231-4. doi: 10.1111/trf.12429. Epub 2013 Sep 30.

PMID:
24117899
40.

Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.

Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, Ardeshna K, Linch DC, Peggs KS; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2014 Jan;164(1):39-52. doi: 10.1111/bjh.12582. Epub 2013 Oct 1. No abstract available.

PMID:
24117159
41.

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.

Cooper CD, Lawrie CH, Liggins AP, Collins GP, Hatton CS, Pulford K, Banham AH.

PLoS One. 2011;6(8):e23916. doi: 10.1371/journal.pone.0023916. Epub 2011 Aug 22.

42.

Radical energy solutions.

Collins GP, Biello D, Minkel JR, Trivedi BP, Ashley S, Choi CQ, Lemonick M.

Sci Am. 2011 May;304(5):38-45. No abstract available.

PMID:
21595402
43.

Solving the cocktail party problem.

Collins GP.

Sci Am. 2011 Apr;304(4):66-7. No abstract available.

PMID:
21495484
44.

A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma.

Medd PG, Clark N, Leyden K, Turner S, Strefford JA, Butler C, Collins GP, Roberts DJ, Atoyebi W, Hatton CS.

Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):230-7. doi: 10.1002/cyto.b.20590. Epub 2011 Apr 1.

45.

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Cabes M, Lawrie CH, Moir D, Hatton C, Banham AH, Pulford K.

Haematologica. 2011 Jan;96(1):78-86. doi: 10.3324/haematol.2010.028241. Epub 2010 Sep 17.

46.

Richter's syndrome of the brain and the spinal cord.

Graves TD, Collins GP, Parry A.

J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):943-4. doi: 10.1136/jnnp.2010.209759. Epub 2010 Jun 28. No abstract available.

PMID:
20587487
47.

Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.

Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG.

Nephrol Dial Transplant. 2010 Feb;25(2):419-26. doi: 10.1093/ndt/gfp488. Epub 2009 Sep 19.

PMID:
19767634
48.

The start of everything.

Musser G, Rusting R, Wong K, Nicholson C, Castelvecchi D, Soares C, Grierson B, Sachs JS, Moyer M, Collins GP, Brown P, Stix G, Wenner M, Hvistendahl M, Yam P, Keats J.

Sci Am. 2009 Sep;301(3):70-94, 96-98, 100. No abstract available.

PMID:
19708530
49.

An iron key to high-temperature superconductivity?

Collins GP.

Sci Am. 2009 Aug;301(2):62-9. No abstract available.

PMID:
19634569
50.

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.

Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, Moir D, Hatton C, Banham AH, Pulford K.

Br J Haematol. 2009 Aug;146(4):396-407. doi: 10.1111/j.1365-2141.2009.07761.x. Epub 2009 Jun 22.

PMID:
19552722

Supplemental Content

Loading ...
Support Center